Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29371783 | 1.00 | PARP1 (1.00) | PARP1PARP2 | |
| SCHEMBL7163790 | 0.91 | PARP1 (0.83) | PARP1 | |
| SCHEMBL7161746 | 0.90 | PARP1 (1.00) | PARP1 | |
| SCHEMBL7164353 | 0.90 | PARP1 (0.81) | PARP1PARP2 | |
| SCHEMBL7165697 | 0.88 | PARP1 (0.79) | PARP1PARP2 | |
| SCHEMBL12231979 | 0.88 | PARP1 (0.80) | PARP1PARP2 | |
| SCHEMBL7160474 | 0.88 | PARP1 (0.78) | PARP1PARP2 | |
| SCHEMBL7156708 | 0.87 | PARP1 (0.81) | PARP1PARP2 | |
| SCHEMBL7159335 | 0.86 | PARP1 (0.75) | PARP1PARP2 | |
| SCHEMBL6200103 | 0.86 | PARP1 (0.80) | PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250160275-A1 | COMPOUNDS FOR MODIFYING MEIOTIC RECOMBINATION AND METHODS RELATING THERETO | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2025-05-22 | — | — | US | claimed |
| WO-2024211130-A1 | METHODS FOR MODIFYING MEIOTIC RECOMBINATION IN PLANTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-10-10 | — | — | WO | claimed |
| EP-4419094-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | Edison Oncology (US) | 2024-08-28 | — | — | EP | claimed |
| WO-2023164606-A1 | COMPOUNDS FOR MODIFYING MEIOTIC RECOMBINATION AND METHODS RELATING THERETO | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-08-31 | — | — | WO | claimed |
| WO-2023069727-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | EDISON ONCOLOGY (US) | 2023-04-27 | — | — | WO | claimed |
| US-11229654-B2 | Combination therapy of tetracyclic quinolone analogs for treating cancer | SENHWA BIOSCIENCES, INC. (TW) | 2022-01-25 | — | — | US | claimed |
| US-11191770-B2 | — | — | 2021-12-07 | — | — | US | claimed |
| CN-112334133-A | Quinolone analogs and salts thereof, compositions, and methods of use thereof | 生华生物科技股份有限公司 | 2021-02-05 | — | — | CN | claimed |
| WO-2019168688-A9 | QUINOLONE ANALOGS AND THEIR SALTS, COMPOSITIONS, AND METHOD FOR THEIR USE | SENHWA BIOSCIENCES, INC. (TW) | 2019-11-14 | — | — | WO | claimed |
| US-20190224209-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | SENHWA BIOSCIENCES, INC. (TW) | 2019-07-25 | — | — | US | claimed |
| US-20250160275-A1 | COMPOUNDS FOR MODIFYING MEIOTIC RECOMBINATION AND METHODS RELATING THERETO | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2025-05-22 | — | — | US | disclosed |
| EP-3377068-B1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | SENHWA BIOSCIENCES INC (TW) | 2025-03-26 | — | — | EP | disclosed |
| WO-2024211130-A1 | METHODS FOR MODIFYING MEIOTIC RECOMBINATION IN PLANTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-10-10 | — | — | WO | disclosed |
| EP-4419094-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | Edison Oncology (US) | 2024-08-28 | — | — | EP | disclosed |
| EP-4249072-A2 | CRYSTALLINE FORMS OF QUINOLONE ANALOGS AND THEIR SALTS | Senhwa Biosciences, Inc. (TW) | 2023-09-27 | — | — | EP | disclosed |
| WO-2005012305-A2 | TRICYCLIC PARP INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| EP-1208104-B1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMA (US) | 2005-01-19 | — | — | EP | disclosed |
| US-6548494-B1 | 3,4-dihydro-2H-(1,4)diazepino(6,7,1-hi)indol-1-one or 1-thione derivatives where indole C3 could also be N; use treating cancers as well as stroke, head trauma, and neurodegenerative diseases | AGOURON PHARMACEUTICALS, INC. | 2003-04-15 | — | — | US | disclosed |
| EP-1208104-A2 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMACEUTICALS, INC. (US) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001016136-A2 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11191770-B2 | — | CXCR4, TLR7, CCR7 | PARP1 2554/4885PARP2 3211/4885 |
| US-20190224209-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | CXCR4, CXCR6, TLR7 | PARP1 1475/4885PARP2 1806/4885 |
| US-11229654-B2 | Combination therapy of tetracyclic quinolone analogs for treating cancer | CXCR4, CXCR6, TLR7 | PARP1 1475/4885PARP2 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.